Alfasigma

Pamlab looks to help improve people's health and quality of life by finding solutions to pharmaceutical needs. The company was founded in Los Angeles, California, United States.

Alfasigma is based in Los Angeles, California, United States.

Pamlab (Alfasigma) acquired ZELNORM in March of 2019. Zelnorm is a prescription pharmaceutical treatment option for irritable bowel syndrome with constipation. The drug works by targeting the 5-HT4 receptor at multiple neurons, and smooth muscle cells in the gastrointestinal tract to induce contraction and relaxation. It also aims to decrease pain signaling.

The company works with drugs such as Deplin L-methylfolate Ca, VSL#3 The Living Shield, Metanx L-methylfolate Ca/P-5-P/Me-Cbl, CerefolinNAC L-methylfolate Ca/Me-Cbl/NAC, CarnitineCarnitine bulk ingredients, Brand Direct Health, PrOxeedPluss, and NeevoDHA.

Pamlab looks to help improve people's health and quality of life by finding solutions to pharmaceutical needs. The company was founded in Los Angeles, California, United States.

The company works with drugs such as Deplin L-methylfolate Ca, VSL#3 The Living Shield, Metanx L-methylfolate Ca/P-5-P/Me-Cbl, CerefolinNAC L-methylfolate Ca/Me-Cbl/NAC, Carnitine bulk ingredients, Brand Direct Health, PrOxeedPluss, and NeevoDHA.

Pamlab (Alfasigma) acquired ZELNORM in March of 2019. Zelnorm is a prescription pharmaceutical treatment option for irritable bowel syndrome with constipation. The drug works by targeting the 5-HT4 receptor at multiple neurons, and smooth muscle cells in the gastrointestinal tract to induce contraction and relaxation. It also aims to decrease pain signaling.

The company acquired DELPIN which is a drug designed to help meet the nutritional needs of people with depression and is usable with antidepressants. It is formulated with L-methylfolate and can be used after initial antidepressant therapy.